Psychedelics
Mindset shareholders will receive $0.75 in cash for each share, representing a premium based on various trading metrics
Hi, what are you looking for?
Mugglehead Magazine
All posts tagged "Mindset Pharma"
Psychedelics
Health Canada granted PharmAla approval to provide its LaNeo product to a physician that will facilitate MDMA-assisted therapy
Canada
PharmAla will have exclusive rights to resell Mindset's cGMP psilocybin to designated researchers
Canada
Cybin will pay Mindset an initial US$500K and 'development milestone payments' that could potentially total US$9.5M afterward
Canada
Discovery of new drugs follows company decision to extend research outside of tryptamine class, i.e. psilocybin and DMT
Psychedelics
Company announces development of novel intranasal formulation with promising efficacy
